The Wolverine Blend: The Complete Guide

For research and educational purposes only. Nothing in this guide constitutes medical advice. Consult a qualified healthcare professional before beginning any new protocol. The Wolverine Blend combines two research compounds — BPC-157 and TB-500 — neither of which is approved by Health Canada or the FDA for the research applications described in this guide.

Last updated: July 2026

---

The Wolverine Blend isn’t a new compound — it’s a convenience product, combining two peptides that were already almost always used together into a single vial. Understanding it well means understanding BPC-157 and TB-500 individually first; this guide focuses specifically on what changes, practically and evidentially, when you buy them pre-combined rather than separately.

Quick Facts

Contains	BPC-157 and TB-500, typically in a 1:1 ratio
Common vial sizes	10mg total (5mg/5mg) or 20mg total (10mg/10mg)
Primary research use	Tissue repair, recovery, both local and systemic
Administration	Subcutaneous or intramuscular
Typical effective range (community-reported)	500mcg of each compound, once daily
Evidence tier	Same as the individual compounds — no blend-specific human trials exist
Regulatory status	Both components named in Health Canada’s April 2026 advisory; both prohibited under WADA at all times

Why These Two, Together

BPC-157 and TB-500 are almost never discussed as competing options — they’re discussed as a pair because their proposed mechanisms address recovery from genuinely different angles. BPC-157 is understood to activate repair more directly at the site of injury — promoting new blood vessel formation, activating collagen-producing cells, and modulating local inflammation. TB-500 is understood to work more systemically, through actin regulation that’s proposed to help mobilize repair-oriented cells from elsewhere in the body toward the site that needs them.

The often-repeated framing is that BPC-157 restores blood flow and repair signaling to damaged tissue, while TB-500 makes sure repair cells actually show up to use it — two different bottlenecks in the same overall process. Whether or not that specific mechanistic division holds up under future controlled research, it’s the consistent rationale behind why these two compounds are packaged together rather than treated as alternatives to each other. For a full breakdown of each compound’s individual evidence and mechanism, see our dedicated BPC-157 and TB-500 guides — this guide focuses specifically on what’s different about using them as a blend.

The Evidence, As a Combination

There is no human trial evidence for the Wolverine Blend as a specific combination — this is worth stating plainly, since it’s easy to assume a well-known named product has been studied as such. What exists is the individual evidence base for each component, covered in full in their respective guides: BPC-157’s extensive but largely unpublished-in-humans preclinical base, and TB-500’s real but mismatched human trial history (belonging to the full-length parent protein in different formulations, not the injectable fragment itself).

A small amount of combined preclinical research does exist — animal studies looking at BPC-157 and TB-500 (or its parent, thymosin beta-4) administered together have found combined administration restoring some measures of tissue function earlier than either compound alone in specific models. This is a genuine, relevant data point, but it’s preclinical and limited in scope — not the kind of evidence that would let anyone make a confident claim about how the combination performs in humans beyond what’s already understood about each compound individually.

Who Shouldn’t Use This

Because this blend combines two compounds, it also combines their individual cautions — there’s no blend-specific safety profile beyond the sum of its parts.

• Personal history of cancer or active malignancy. Both components carry the same theoretical pro-angiogenic caution individually, and combining them doesn’t reduce that theoretical concern — if anything, it’s worth taking at least as seriously as with either compound alone.
• Competitive athletes subject to drug testing. Both BPC-157 and TB-500 are independently confirmed on the WADA Prohibited List, at all times, under separate but related categories. Using the blend carries the same anti-doping exposure as using either component alone — there’s no scenario where combining them reduces that risk.
• Pregnancy or breastfeeding. No human safety data exists for either component in this context.

See our individual BPC-157 and TB-500 guides for the complete picture on each compound’s specific safety considerations.

Common Myths, Addressed

“The Wolverine Blend has been specifically tested and shown to work.” Not accurately — no blend-specific human trials exist. What’s been studied, to varying degrees, are the individual components, and to a much smaller extent, the two administered together in animal models.

“Since it combines two compounds, you get roughly double the effect of one.” Not how the mechanisms are understood to work. BPC-157 and TB-500 are proposed to address different parts of the repair process rather than amplifying the same effect — the rationale is complementary coverage, not additive potency.

“A pre-blended vial is strictly more convenient with no downsides.” Convenience is real, but so is a genuine tradeoff — see “Blend vs. Buying Separately” below.

What Researchers Are Actually Experiencing

Community-reported tolerability for the blend closely mirrors what’s reported for each compound individually — injection site reactions and, less commonly, mild fatigue after higher TB-500-equivalent doses are the most frequently mentioned effects, with no clearly distinct combined-effect profile beyond what each compound produces on its own.

One practical note that comes up specifically in the context of using both compounds together, whether blended or drawn separately: BPC-157 and TB-500 are generally considered pH-compatible and can be combined in the same syringe if administered from separate vials, which is part of why the pre-blended format doesn’t offer a dramatic administration advantage over drawing both from individual vials into one injection.

This section reflects patterns commonly discussed across community research spaces. It’s observational rather than clinical trial data, and individual experience varies.

The Practical Basics

Research Ranges

Protocol	Research Range	Frequency
Standard	500mcg of each compound	Once daily, subcutaneous
Conservative	250mcg of each compound	Once daily, subcutaneous
Acute loading	250–500mcg of each compound	Twice daily, first 1–2 weeks

These ranges mirror each compound’s individual standard dose — the blend format doesn’t change the effective dose of either component, it just delivers both in one injection at a fixed ratio.

Worked Dose Math

At a 1:1 ratio, 20mg total (10mg BPC-157 + 10mg TB-500) reconstituted with 2mL BAC water — a standard 3mL vial capacity — gives a combined concentration of 10mg/mL, or 5mg/mL of each individual compound:

• 250mcg of each compound → 0.05mL → 5 units (delivers 250mcg BPC-157 + 250mcg TB-500 together)
• 500mcg of each compound → 0.1mL → 10 units (delivers 500mcg BPC-157 + 500mcg TB-500 together)

The underlying rule is the same as any single-compound calculation: volume (mL) = dose (mg) ÷ concentration (mg/mL), then ×100 for units on a U-100 syringe — just remember that each unit drawn delivers both compounds simultaneously, at whatever ratio the vial was blended to.

Vial Planning

A 20mg vial (10mg/10mg) at 5mg/mL of each compound gives you 10mg of each total. At a steady 500mcg of each per day, that’s 20 days per vial.

Reconstitution and Storage — The Short Version

The Wolverine Blend reconstitutes with standard BAC water, refrigerates at 2–8°C, and should be used within 28 days — the same standard approach used across nearly every compound in this series, including both of this blend’s components. For the complete process, see our dedicated reconstitution and storage guide.

Sourcing

Sourcing a blend deserves a specific extra layer of scrutiny beyond what applies to a single-compound vial: a complete Certificate of Analysis for a blend should confirm the identity and purity of both components independently, not just an overall purity figure. A COA that doesn’t separately verify each compound tells you meaningfully less than one that does. See our full guide on reading a Certificate of Analysis and vetting a vendor for the general framework this builds on.

Administration

Subcutaneous injection is standard for systemic recovery applications; intramuscular injection near a specific injury site is used by some researchers for more targeted effects, following the same rationale described in the individual BPC-157 and TB-500 guides. No fasting requirement.

Best Practices

• Verify both components on the COA independently — this is the single most important sourcing habit specific to any blended product.
• Track total dose per compound, not just total injection volume — it’s easy to lose track of the individual BPC-157 and TB-500 amounts when they’re delivered together.
• Consider whether a blend actually fits your plans before ordering — see the tradeoffs below.
• Track your protocol from day one — dose, injection date, and observed effects, at minimum.

Blend vs. Buying Separately

This is worth thinking through deliberately rather than defaulting to the blend for convenience.

The case for the blend: one injection instead of two, one vial to store and track instead of two, and no need to calculate and combine two separate draws each time. For a researcher who’s already decided they want both compounds at a fixed, standard ratio, this is a genuine simplification.

The case for separate vials: you can adjust each compound’s dose independently rather than being locked into whatever ratio the vial was blended to — useful if you want to taper TB-500 while continuing BPC-157, or run different relative doses than the standard 1:1 split. You can also verify and track each compound’s concentration and COA independently with more clarity, since a blended vial’s combined documentation requires more careful reading to confirm both components separately. If your research plans might involve adjusting the two compounds independently over time, separate vials preserve that flexibility in a way a fixed-ratio blend doesn’t.

Neither choice is more “correct” — it depends on whether you want simplicity at a fixed ratio, or flexibility at the cost of managing two vials.

Common Mistakes to Avoid

• Assuming the blend ratio matches what you’d choose if dosing independently — most blends use a straightforward 1:1 ratio, which may not match every researcher’s individual preference for each compound.
• Not confirming both components independently on the COA, and accepting a single overall purity figure as sufficient.
• Losing track of per-compound dosing when the two are combined in one syringe draw.
• Not recording the reconstitution volume, turning every future dose calculation into a guess.

What Happens If You Stop

As with each individual component, there’s no dedicated discontinuation research for the blend. Consistent with how both compounds are typically used — tied to a specific recovery objective rather than as an indefinite standing intervention — most community use frames stopping as the natural end of a defined protocol window rather than something expected to produce a rebound effect.

What to Expect, Week by Week

This follows the same general pattern described in the individual BPC-157 and TB-500 guides — no dramatic early effect in the first week, with community reports of noticeable recovery changes for injury-focused objectives most commonly appearing in the two-to-four-week range, varying considerably by injury type and severity.

Common Questions

Is the Wolverine Blend a different compound from BPC-157 and TB-500 individually? No — it’s the same two compounds, pre-combined in one vial at a fixed ratio, typically 1:1. Nothing about the underlying molecules changes when they’re blended.

Does blending them create a new or different effect? Not based on current understanding — the two compounds are believed to work through independent, complementary mechanisms rather than interacting to produce something neither achieves alone. The rationale is complementary coverage, not a synergistic new effect.

Can I just draw BPC-157 and TB-500 from separate vials into the same syringe instead of buying a blend? Yes — the two are generally considered pH-compatible for this purpose, which is part of why a pre-blended vial’s convenience advantage over separate vials is smaller than it might first appear.

Is the blend legal to source in Canada? Both components are subject to the same considerations described in our Canadian regulatory guide, and both were named in Health Canada’s April 2026 advisory individually. Combining them into one product doesn’t change that underlying status.

Before You Start

A quick checklist to run through before your first dose:

• [ ] Reviewed the individual contraindications and cautions for both BPC-157 and TB-500
• [ ] Confirmed you’re not subject to competitive drug testing, or accepted that risk knowingly for both components
• [ ] Confirmed your COA verifies both compounds independently, not just a combined purity figure
• [ ] Decided whether a fixed-ratio blend or separate vials better fits your research plans
• [ ] Have a tracking method ready for per-compound dose, injection date, and observed effects

Want this as a printable checklist alongside our compound reference plate? Download both from the resources section.

Common Protocol at a Glance

Protocol	Dose (each compound)	Frequency
Conservative	250mcg	Once daily
Standard	500mcg	Once daily
Acute loading	250–500mcg	Twice daily, first 1–2 weeks

Where to Go From Here

• BPC-157: The Complete Guide
• TB-500: The Complete Guide
• The Regenerative Compound Group — BPC-157, TB-500, GHK-Cu, and KPV compared in full
• GLOW and KLOW — blends that build on this same combination
• Our Reconstitution and Storage Guide
• Our Certificate of Analysis and Vendor Verification Guide

---

This guide reflects the evidence and community research patterns available as of publication and will be updated periodically as new research emerges. It is provided for research and educational purposes only, does not constitute medical advice, and is not a substitute for consultation with a qualified healthcare professional. Aethon Labs does not intend for any compound discussed here to be used for human consumption.

AETHON LABS — Tested. Documented. Delivered.